Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements With and Without Central Nervous System Metastases

The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC). The participants will self

progressive disease
kinase inhibitor
cancer chemotherapy
lung carcinoma
ROS1
  • 0 views
  • 27 Oct, 2022
  • 50 locations
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor (TKI), has been shown to be effective in tumors in several retrospective studies. Recently the FDA approved

  • 0 views
  • 04 Oct, 2022
  • 39 locations
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)

Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement. Alectinib

  • 0 views
  • 29 Apr, 2022
  • 30 locations
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or

  • 0 views
  • 15 Jun, 2022
  • 1 location
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and

refractory neuroblastoma
cancer
filgrastim
bone marrow procedure
topotecan
  • 158 views
  • 29 May, 2022
  • 14 locations
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

cancer
adenocarcinoma
pembrolizumab
pemetrexed
paclitaxel
  • 1154 views
  • 21 Oct, 2022
  • 1027 locations
Crizotinib Continuation Clinical Study

The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned

crizotinib
  • 0 views
  • 07 Oct, 2022
  • 1 location
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes

squamous non-small cell lung cancer
measurable disease
ROS1
crizotinib
cancer
  • 0 views
  • 18 Dec, 2021
  • 1 location
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

advanced endometrial cancer. There is no standard protocol for the second-line option when tumors persist or recur. In vitro and in vivo studies showed Crizotinib, an approved drug for the treatment of ALK

  • 0 views
  • 14 Jun, 2022
  • 1 location
Talazoparib and Palbociclib Axitinib or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors TalaCom Trial

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of talazoparib when given in combination with palbociclib, axitinib, or crizotinib in treating patients

  • 0 views
  • 27 Nov, 2021
  • 1 location